{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"19.4","value":"10.4"},{"groupId":"OG001","lowerLimit":"6.1","upperLimit":"25.4","value":"13.8"},{"groupId":"OG002","lowerLimit":"3.6","upperLimit":"19.9","value":"9.7"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.4","upperLimit":"45.4","value":"33.8"},{"groupId":"OG001","lowerLimit":"22.5","upperLimit":"48.1","value":"34.5"},{"groupId":"OG002","lowerLimit":"18.2","upperLimit":"41.9","value":"29.0"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"62"}],"units":"Participants"}],"description":"the best response designation over the study as a whole, recorded between the date of first dose and the last efficacy assessment prior to subsequent therapy.\n\nMeasured in Complete Response and Partial Response","dispersionType":"95% Confidence Interval","groups":[{"description":"3mg/kg of nivolumab","id":"OG000","title":"Nivolumab Monotherapy (Expansion)"},{"description":"3 mg/kg of nivolumab and\n\n1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W","id":"OG002","title":"Nivolumab + Lirilumab"}],"paramType":"NUMBER","populationDescription":"All treated participants with available measurements (excluding Multiple Myeloma (MM) Group)","reportingStatus":"POSTED","timeFrame":"Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month","title":"Best Overall Response","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}